# Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

> **NCT05635604** · NA · COMPLETED · sponsor: **Danish Headache Center** · enrollment: 38 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Eptinezumab
- **DRUG:** PACAP-38

## Key facts

- **NCT ID:** NCT05635604
- **Lead sponsor:** Danish Headache Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2023-08-04
- **Final completion:** 2023-08-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05635604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05635604, "Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05635604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*